NAT10 and hepatocellular carcinoma: HALP, a novel marker reflecting the inflammatory, nutritional, and immune status of the body by integrating conventional hematological markers including hemoglobin, albumin, lymphocyte, and platelets, has been employed to predict the clinical outcome of hepatocellular carcinoma [19], lung cancer [31], and esophageal cancer [17], etc. However, to our knowledge, no previous studies have reported on the prognostic significance of the HALP score in BC patients.